Compare Recursion Pharmaceuticals Inc (RXRX) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs iShares Silver Trust — how do they compare? Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B), while iShares Silver Trust trades at $54.53 (market cap $29.58B). The key difference: iShares Silver Trust is far larger — about 12.8× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is more actively traded (40,478,768 versus 20,364,955). Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and iShares Silver Trust for 89 Days on average.
| RXRX | SLV | |
|---|---|---|
Market Cap | $2.31B | $29.58B |
Volume | 40,478,768 | 20,364,955 |
Sector | Health | — |
52-Week High | $6.79 | $105.57 |
52-Week Low | $2.84 | $42.40 |
Typical Hold Time | 22 Days | 89 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
SLV (iShares Silver Trust) is trading at $53.82, down 2.94% amid broader precious metals pressure from rising Treasury yields and Fed rate hike expectations. The ETF shows minimal operational activity with $0 revenue but maintains a strong balance sheet with $13.41 billion in assets against negligible liabilities. Technical indicators signal bearish momentum with moving averages overwhelmingly negative, though RSI levels suggest potential oversold conditions.
While silver faces near-term headwinds from monetary policy, structural demand from industrial applications and inflation hedging provides long-term support. Key risks include Fed policy volatility and dollar strength, but the trust's pure-play silver exposure offers strategic diversification. Current levels may present accumulation opportunities for investors with multi-year horizons.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
